13. BARDA

On September 25, 2026, the Company entered into the BARDA Contract with BARDA, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to support the development of SCY-247, the Company’s second-generation fungerp antifungal candidate.

The BARDA Contract provides for potential total non-dilutive funding by BARDA of up to $213.9 million. The initial base period of the BARDA Contract commences in September 2026 and provides approximately $18.5 million to support the advancement of oral and intravenous SCY-247 into a Phase 2 study in patients with invasive candidiasis. The balance of the

award is subject to BARDA exercising up to six options which could extend the term of the BARDA Contract for up to ten years. If all options are exercised, the BARDA Contract could fund the development of SCY-247 from its current stage through NDA submissions to the FDA for two indications: treatment of invasive candidiasis and prevention of invasive fungal infections in high-risk patients.

The BARDA Contract is structured as a cost-share arrangement, with BARDA providing support for eligible SCY-247 costs, including both direct and general and administrative expenses. The Company expects to fund its share of near-term program costs for SCY-247 within its existing operating plan. The BARDA Contract contains terms and conditions that are customary for contracts with BARDA of this nature. BARDA may terminate the BARDA Contract for convenience at any time.